You are here
FDA Accepts for Filing Clobetasol Propionate NDA
April 8, 2004
PALO ALTO, Calif., April 8 /PRNewswire-FirstCall/ -- Connetics Corporation (Nasdaq: CNCT - News), a specialty pharmaceutical company focused on dermatology, today announced that it has received confirmation that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company's New Drug Application (NDA) for Extina(TM), as of January 26, 2004 with a user fee goal date of September 24, 2004.
Extina is an investigational new drug formulation of 2% ketoconazole delivered in the Company's proprietary VersaFoam(TM) delivery system, as a potential new treatment for seborrheic dermatitis.
Source: Connetics Corporation
Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs